Description
The RI7217 monoclonal antibody specifically recognizes the mouse Transferrin Receptor (TfR, Trfr, or TR), which is also known as Transferrin Receptor protein 1 (TfR1), CD71, and Mammary tumor virus receptor 1 (Mtvr-1 or Mtvr1). CD71 is a ~95-kDa single-pass type II transmembrane glycoprotein that is encoded by Tfrc and expressed on the cell surface as a disulfide-linked homodimer. The CD71 monomer is comprised of an extracellular C-terminal domain with a transferrin binding site followed by a transmembrane region and an N-terminal cytoplasmic tail that is involved in mediating the endocytosis and recycling of the receptor. This receptor mediates cellular iron uptake via endocytosis of an iron-transferrin complex followed by the recycling of transferrin and the receptor to the cell surface. CD71 is lowly expressed on most nonactivated cells including resting B and T lymphocytes. CD71 expression is upregulated on activated and proliferating cells such as mitogen- or antigen-stimulated B cells and T cells as well as some tumor cells. CD71 is variably expressed on erythroid precursors from pronormoblasts (proerythroblasts) to reticulocytes and is absent on mature red blood cells. CD71 is expressed on erythroid precursors that utilize iron for heme synthesis. CD71 can also serve as an entry receptor for several viral infections including those caused by Mouse mammary tumor virus (MMTV). The RI7217 antibody can reportedly be used to inhibit cellular proliferation.
BD™ CompBeads can be used as surrogates to assess fluorescence spillover (Compensation). When fluorochrome conjugated antibodies are bound to CompBeads, they have spectral properties very similar to cells. However, for some fluorochromes there can be small differences in spectral emissions compared to cells, resulting in spillover values that differ when compared to biological controls. It is strongly recommended that when using a reagent for the first time, users compare the spillover on cells and CompBead to ensure that BD Comp beads are appropriate for your specific cellular application. For optimal and reproducible results, BD Horizon Brilliant Stain Buffer should be used anytime two or more BD Horizon Brilliant dyes are used in the same experiment. Fluorescent dye interactions may cause staining artifacts which may affect data interpretation. The BD Horizon Brilliant Stain Buffer was designed to minimize these interactions. More information can be found in the Technical Data Sheet of the BD Horizon Brilliant Stain Buffer (Cat. No. 563794/566349) or the BD Horizon Brilliant Stain Buffer Plus (Cat. No. 566385).
Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated to the dye under optimum conditions that minimize unconjugated dye and antibody.
1. The production process underwent stringent testing and validation to assure that it generates a high-quality conjugate with consistent performance and specific binding activity. However, verification testing has not been performed on all conjugate lots.
2. Researchers should determine the optimal concentration of this reagent for their individual applications.
3. An isotype control should be used at the same concentration as the antibody of interest.
4. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
5. For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
6. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
7. BD Horizon Brilliant Stain Buffer is covered by one or more of the following US patents: 8,110,673; 8,158,444; 8,575,303; 8,354,239.
8. Please refer to http://regdocs.bd.com to access safety data sheets (SDS).
9. Pacific Blue™ is a trademark of Molecular Probes, Inc., Eugene, OR.
10. BD Horizon Brilliant Violet 421 is covered by one or more of the following US patents: 8,158,444; 8,362,193; 8,575,303; 8,354,239.
